TP53 and breast cancer: In this report, TP53 signature had a robust capacity for predicting prognosis in early-stage breast cancer compared to other gene expression profiles including Mammaprint and Oncotype DX [13], which have previously been used as gene expression profile panels to predict early-stage breast cancer in clinical situations [14–18].